Statera Biopharma Inc (STAB PINK) stock market data APIs
$0.0001
0(0%)
as of January 14, 2025
Statera Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. operates as a subsidiary of Biostax Corp.
Prev. Close
0.0001
Open
0.0001
Volume
0
High
0.0001
Low
0.0001
52 wk Range
0.0001-0.0008
Market Cap
7 142
Shares Outstanding
71 416 K
Revenue
3 688 K
EPS
0
Beta
261.464
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Statera Biopharma Inc data using free add-ons & libraries
Get Statera Biopharma Inc Fundamental Data
Statera Biopharma Inc Fundamental data includes:
- Net Revenue: 3 688 K
- EBITDA: -20 583 648
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-05-17
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Statera Biopharma Inc News
New
Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs
FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune thera...
Nasdaq Resumes Trading in Statera Biopharma, Inc.
NEW YORK, Aug. 26, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading resumed in Statera Biopharma, Inc. (Nasdaq: STAB) today, August 26, 2022 at 7:10 a.m. East...
Nasdaq Resumes Trading in Statera Biopharma, Inc.
Nasdaq, Inc. NEW YORK, Aug. 26, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading resumed in Statera Biopharma, Inc. (Nasdaq: STAB) today, August 26, 2022 at 7:...
Nasdaq Halts Statera Biopharma, Inc.
NEW YORK, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted today in Statera Biopharma, Inc. (Nasdaq: STAB) at 11:01:52 A.M. Eastern Time f...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
